Home Biosimilar Antibodies Immunology & Inflammation Interleukins Risankizumab (anti-IL-23)
For research use only. Not for use in humans.

Risankizumab (anti-IL-23)

Synonyms: SGRF,IL23

Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease.

Risankizumab (anti-IL-23)

Click to purchase the isotype control of Risankizumab (anti-IL-23)

Quality Control

Batch: Purity: 99% Protein concentration: 8.131mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Risankizumab targets the p19 subunit of IL-23. Risankizumab is indicated for the treatment of psoriasis and is safe and effective in maintaining remission in active Crohn's disease.

Product Details

CAS No. 1612838-76-2
Molecular Weight 150 kDa
Isotype human IGg1, κ
Application Risankizumab (anti-IL-23)
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07071519 RECRUITING Drug: Risankizumab|Drug: Risankizumab Ulcerative Colitis AbbVie 2025-07-28 PHASE3
NCT07697456 RECRUITING Drug: Risankizumab|Drug: Trosunilimab|Drug: ABBV-701 Crohn's Disease; Ulcerative Colitis AbbVie 2026-07-31 PHASE2
NCT07352566 NOT_YET_RECRUITING Drug: Triamcinolone|Drug: 5-Fluorouracil|Drug: Calcipotriene Psoriasis; Atopic Dermatitis University of California, San Francisco 2026-08-01 PHASE4
NCT06548542 RECRUITING Drug: Risankizumab|Drug: Lutikizumab|Drug: Trosunilimab|Drug Crohn's Disease AbbVie 2024-09-04 PHASE2
NCT05995353 RECRUITING Drug: Risankizumab|Drug: Risankizumab Crohn's Disease AbbVie 2023-12-11 PHASE3
NCT03105102 ACTIVE_NOT_RECRUITING Drug: Placebo for Risankizumab SC|Drug: Risankizumab IV|Drug Crohn's Disease AbbVie 2018-04-09 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-09-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.